Our Commitment to End Animal Testing
Drug and cosmetic developers are still mandated to test on animals, even if it doesn't benefit the science.
This leads to the experimentation on and death of hundreds of millions of primates, dogs, rabbits, mice and other animals.
Here's how BICO is replacing outdated methods for drug discovery to end animal testing once and for all.
3D BIOPRINTING
Fabricate human tissue samples that provide more physiologically relevant drug testing than animals.
automated precision dispensing
Accurately & reproducible distribute physiologically relevant biological material.
In Vitro assays for drug screening and toxicity assessment
High content screening, confocal microscopy, ELISA, and other assays.
single large-particle sorting and dispensing
Handling complex 3D cellular models such as spheroids, organoids which can replace animal testing in pre-clinical research.
BICO endorses the FDA Modernization Act
Allowing drug and cosmetic makers to develop new products using non-animal models.
Contact your representative
Take action and help pass the FDA Modernization Act today
We have endorsed the bipartisan FDA Modernization Act of 2021 in the United States. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modeling, and other human biology-based test methods.
Initiatives at a glance
November 24, 2021
Creating awareness on how to reduce animal testing
CELLINK has joined The Swedish 3Rs Center (Replace, Reduce and Refine), network that facilitates contact and information sharing on animal-free methods to educate the research community of the humane biological methods available to improve drug development efficiency and effectiveness.
December 14, 2021
BICO Endorses FDA Modernization Act of 2021
BICO announced today it is endorsing the bipartisan FDA Modernization Act of 2021. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modelling, and other human biology-based test methods.
September 30, 2022
The US senate has passed the FDA Modernization Act
A massive stride in the acceptance of alternatives to animal models in drug discovery. Alternatives that capture human physiology better, that are more ethical, sustainable and most importantly, alternatives that can accelerate the discovery of life changing therapies. Alternatives that our bioprinters have proudly supported and enabled since our inception. Alternatives that we are committed to continuing to develop and democratize.
